RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Keros Therapeutics - Stock

Keros Therapeutics Net Income 2024

Keros Therapeutics Net Income

-178.81 M USD

Keros Therapeutics Dividend yield

Ticker

KROS

ISIN

US4923271013

WKN

A2P2YF

In 2024, Keros Therapeutics's profit amounted to -178.81 M USD, a 16.88% increase from the -152.99 M USD profit recorded in the previous year.

The Keros Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e188.42
2028e16.71
2027e-114.21
2026e-173.18
2025e-189.85
2024e-178.81
2023-152.99
2022-104.68
2021-58.74
2020-45.36
2019-12.34
2018-1.34

Keros Therapeutics Aktienanalyse

What does Keros Therapeutics do?

Keros Therapeutics Inc is a biopharmaceutical company that was founded in 2015 by five biotechnology industry experts. The company is based in Lexington, Massachusetts. Keros is an emerging company that focuses on developing innovative therapies for severe diseases resulting from genetic defects. The business model of Keros Therapeutics Inc is to expand its pipeline of innovative therapies through the research, development, and commercialization of drugs that have highly specific mechanisms of action. Keros' business model aims to develop new and differentiated therapies that focus on modulating biological signals and pathways to improve the treatment of serious diseases. Keros Therapeutics Inc has several divisions that focus on different areas of biotechnology. One division of Keros specializes in the development of RNA-modulating therapies for diseases with genetic defects. These therapies target the modulation of RNA splicing processes to influence the causal factor of severe diseases. Another division of Keros focuses on the development of drugs that target the Wnt signaling pathway, a complex protein signaling network that plays an important role in many processes in the body. These Wnt-related drugs target various disease areas such as cancer and fibrosis to improve the treatment of these conditions. The company is currently in the clinical phase and has brought several products to market in various stages of research. One of Keros' key drug candidates is KER-012, a medication for the treatment of Alpha-1 antitrypsin deficiency, a rare and severe disease that often leads to lung and liver conditions. KER-012 aims to develop more effective treatment options for patients by specifically influencing an RNA splicing mechanism in the cells that is associated with the disease. Another drug candidate from Keros is KER-047, a medication for the treatment of Neurofibromatosis type 1, a rare condition that causes tumors in the nervous system. It targets the Wnt signaling pathway to restore control over tumor proliferation and enlargement. Keros has also established partnerships with other biotechnology companies and academic institutions to expand its research and development capabilities and diversify its pipeline. One notable agreement is the collaboration with Arbutus Biopharma to develop RNA modulators for cardiovascular diseases. Overall, Keros Therapeutics Inc aims to develop innovative and effective therapies for a variety of diseases by focusing on biology and signaling pathways that are responsible for disease progression. With a solid therapy pipeline and an experienced group of biotechnology experts, Keros could soon become a leading company in the biopharmaceutical industry. Keros Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Keros Therapeutics's Profit Margins

The profit margins of Keros Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Keros Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Keros Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Keros Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Keros Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Keros Therapeutics Stock

How much profit has Keros Therapeutics made this year?

Keros Therapeutics has made -178.81 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 16.88% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Keros Therapeutics publish its earnings?

Keros Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Keros Therapeutics?

The profits of Keros Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Keros Therapeutics?

You can learn more about the earnings of Keros Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Keros Therapeutics pay?

Over the past 12 months, Keros Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Keros Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Keros Therapeutics?

The current dividend yield of Keros Therapeutics is .

When does Keros Therapeutics pay dividends?

Keros Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Keros Therapeutics?

Keros Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Keros Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Keros Therapeutics located?

Keros Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Keros Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Keros Therapeutics from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Keros Therapeutics pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Keros Therapeutics in the year 2023?

In the year 2023, Keros Therapeutics distributed 0 USD as dividends.

In which currency does Keros Therapeutics pay out the dividend?

The dividends of Keros Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Keros Therapeutics

Our stock analysis for Keros Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Keros Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.